VOR Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

The Citizens JMP Life Sciences Conference

Fireside Chat: Tuesday, May 14, 2024 at 11:00 am ET

Location: New York, NY

A live webcast and archived replay of the fireside chat will be available on the investors section of .

H.C. Wainwright 2nd Annual BioConnect Investor Conference

Fireside Chat: Monday, May 20, 2024 at 10:30 am ET

Location: New York, NY

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .

Contact:

Media & Investors

Sarah Spencer





EN
06/05/2024

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company’s leadership team. “We are thrilled to welcome Jeremy to Vor Bio,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairm...

19h / 2m 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 113,478 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 24,319 shares of Vor Bio’s common stock to 20 newly hired employees. The foregoing stock options...

October 31, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Prof...

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living (MG-ADL) improvement, with a mean reduction of -7.5 points Sustained efficacy and favorable safety extension data support potential global best-in-disease profile in generalized myasthenia gravis (gMG) BOSTON, Oct. 29,...

October 29, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Da...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331). During the webcast, Vor Bio management, ...

October 22, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA...

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025 CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), which evaluated telitacicept in adults with IgA neuropathy (IgAN), will be presented as a late-breaking oral presentation a...

October 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch